Predicting the risk of disease recurrence and death following curative-intent radiotherapy for non-small cell lung cancer: the development and validation of two scoring systems from a large multicentre UK cohort
Authors
Evison, M.Barrett, E.
Cheng, A.
Mulla, A.
Walls, G.
Johnston, D.
McAleese, J.
Moore, K.
Hicks, J.
Blyth, K.
Denholm, M.
Magee, L.
Gilligan, D.
Silverman, S.
Hiley, C.
Qureshi, M.
Clinch, H.
Hatton, M.
Philipps, L.
Brown, S
O'Brien, M.
McDonald, F.
Faivre-Finn, Corinne
Affiliation
Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.Issue Date
2020
Metadata
Show full item recordAbstract
Aims: There is a paucity of evidence on which to produce recommendations on neither the clinical nor the imaging follow-up of lung cancer patients after curative-intent radiotherapy. In the 2019 National Institute for Health and Care Excellence lung cancer guidelines, further research into risk-stratification models to inform follow-up protocols was recommended. Materials and methods: A retrospective study of consecutive patients undergoing curative-intent radiotherapy for non-small cell lung cancer from 1 October 2014 to 1 October 2016 across nine UK trusts was carried out. Twenty-two demographic, clinical and treatment-related variables were collected and multivariable logistic regression was used to develop and validate two risk-stratification models to determine the risk of disease recurrence and death. Results: In total, 898 patients were included in the study. The mean age was 72 years, 63% (562/898) had a good performance status (0-1) and 43% (388/898), 15% (134/898) and 42% (376/898) were clinical stage I, II and III, respectively. Thirty-six per cent (322/898) suffered disease recurrence and 41% (369/898) died in the first 2 years after radiotherapy. The ASSENT score (age, performance status, smoking status, staging endobronchial ultrasound, N-stage, T-stage) was developed, which stratifies the risk for disease recurrence within 2 years, with an area under the receiver operating characteristic curve (AUROC) for the total score of 0.712 (0.671-0.753) and 0.72 (0.65-0.789) in the derivation and validation sets, respectively. The STEPS score (sex, performance status, staging endobronchial ultrasound, T-stage, N-stage) was developed, which stratifies the risk of death within 2 years, with an AUROC for the total score of 0.625 (0.581-0.669) and 0.607 (0.53-0.684) in the derivation and validation sets, respectively. Conclusions: These validated risk-stratification models could be used to inform follow-up protocols after curative-intent radiotherapy for lung cancer. The modest performance highlights the need for more advanced risk prediction tools.Citation
Evison M, Barrett E, Cheng A, Mulla A, Walls G, Johnston D, et al. Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort. Clin Oncol (R Coll Radiol). 2020.Journal
Clinical OncologyDOI
10.1016/j.clon.2020.09.001PubMed ID
32978027Additional Links
https://dx.doi.org/10.1016/j.clon.2020.09.001Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2020.09.001
Scopus Count
Collections
Related articles
- A comparison of machine learning methods for predicting recurrence and death after curative-intent radiotherapy for non-small cell lung cancer: Development and validation of multivariable clinical prediction models.
- Authors: Hindocha S, Charlton TG, Linton-Reid K, Hunter B, Chan C, Ahmed M, Robinson EJ, Orton M, Ahmad S, McDonald F, Locke I, Power D, Blackledge M, Lee RW, Aboagye EO
- Issue date: 2022 Mar
- The Quality of Curative-intent Radiotherapy for Non-small Cell Lung Cancer in the UK.
- Authors: McAleese J, Baluch S, Drinkwater K
- Issue date: 2015 Sep
- Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.
- Authors: Fornacon-Wood I, Banfill K, Ahmad S, Britten A, Carson C, Dorey N, Hatton M, Hiley C, Thippu Jayaprakash K, Jegannathen A, Kidd AC, Koh P, Panakis N, Peedell C, Peters A, Pope A, Powell C, Stilwell C, Thomas B, Toy E, Wicks K, Wood V, Yahya S, Price G, Faivre-Finn C
- Issue date: 2023 Oct
- Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The development and validation of the LNC-PATH score.
- Authors: Balata H, Foden P, Edwards T, Chaturvedi A, Elshafi M, Tempowski A, Teng B, Whittemore P, Blyth KG, Kidd A, Ellames D, Flint LA, Robson J, Teh E, Jones R, Batchelor T, Crosbie P, Booton R, Evison M
- Issue date: 2018 Nov
- Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
- Authors: Punjabi A, Barrett E, Cheng A, Mulla A, Walls G, Johnston D, McAleese J, Moore K, Hicks J, Blyth K, Denholm M, Magee L, Gilligan D, Silverman S, Qureshi M, Clinch H, Hatton M, Philipps L, Brown S, O'Brien M, McDonald F, Faivre-Finn C, Hiley C, Evison M
- Issue date: 2021 Aug